Factors affecting efficacy of pegylated interferon alpha-2a in chronic hepatitis C patients with serotype 2
-
- Irishio Keiko
- Department of Clinical Research, Ikeda Municipal Hospital
-
- Imai Yasuharu
- Department of Gastroenterology, Ikeda Municipal Hospital
-
- Mita Eiji
- Department of Gastroenterology and Hepatology, National Hospital Organization, Osaka National Hospital
-
- Toyama Takashi
- Department of Gastroenterology and Hepatology, National Hospital Organization, Osaka National Hospital
-
- Kuzushita Noriyoshi
- Department of Gastroenterology and Hepatology, National Hospital Organization, Osaka National Hospital
-
- Nagase Toshihiko
- Department of Internal Medicine, Suita Municipal Hospital
-
- Doi Yoshinori
- Department of Gastroenterology, Otemae Hospital
-
- Yamada Akira
- Department of Gastroenterology, Sumitomo Hospital
-
- Kato Michio
- Department of Internal Medicine, National Hospital Organization, Minami Wakayama Medical Center
-
- Fukuda Kazuto
- Department of Gastroenterology, Ikeda Municipal Hospital
-
- Igura Takumi
- Department of Gastroenterology, Ikeda Municipal Hospital
-
- Sawai Yoshiyuki
- Department of Gastroenterology, Ikeda Municipal Hospital
-
- Kogita Sachiyo
- Department of Gastroenterology, Ikeda Municipal Hospital
-
- Hiramatsu Naoki
- Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine
-
- Takehara Tetsuo
- Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine
-
- Hayashi Norio
- Department of Gastroenterology, Kansai Rosai Hospital
Bibliographic Information
- Other Title
-
- セロタイプ２型のＣ型慢性肝炎に対するＰＥＧ－ＩＦＮα－２ａ単独療法の有効性に関する検討
- セロタイプ 2ガタ ノ Cガタ マンセイ カンエン ニ タイスル PEG IFN アルファ 2a タンドク リョウホウ ノ ユウコウセイ ニ カンスル ケントウ
Search this article
Abstract
We retrospectively investigated factors affecting efficacy of peginterferon alpha-2a in 70 patients with chronic hepatitis C with serotype 2. Overall sustained virological response (SVR) rate was 77.1% by intent-to-treat analysis. SVR rates were 89.6% and 90.9% when negativity of serum HCV-RNA was obtained at 4 and 8 weeks after beginning the treatment, respectively, whereas SVR rate in patients whose serum HCV-RNA was positive at 8 weeks was 20.0%. Multivariate regression analysis revealed that pretreatment serum HCV-RNA level and negativity of HCV-RNA at 8 weeks after initiating treatment were independent factors associated with SVR. The SVR rate of patients with serum HCV-RNA level less than 1000 KIU/mL was 88.7%. These results suggest that high SVR rate can be expected in patients with pretreatment serum HCV-RNA level under 1000 KIU/mL and negative serum HCV-RNA at 8 weeks after beginning the treatment in patients with serotype 2 chronic hepatitis C.<br>
Journal
-
- Kanzo
-
Kanzo 52 (4), 236-243, 2011
The Japan Society of Hepatology
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390282679771567872
-
- NII Article ID
- 10029285306
-
- NII Book ID
- AN00047770
-
- ISSN
- 18813593
- 04514203
-
- NDL BIB ID
- 11056292
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- NDL
- Crossref
- CiNii Articles
-
- Abstract License Flag
- Disallowed
